Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rosalee Unwin (NPI 1336555234)

Field	Value
Entity Type	Individual
Organization	Rosalee Unwin
Address	171 Ashley Ave
City	Charleston
State	SC
ZIP	29425
Taxonomy	Family Nurse Practitioner
NPI Enumerated	July 11, 2014

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: reported lifetime Medicare revenue is $2.9M and there is no Medicaid billing on file, so patient mix and revenue exposure are concentrated entirely in Medicare. Analysts should treat this profile as Medicare‑centric when assessing network value or contract negotiations.

Revenue concentration is significant within a small set of biologic administration codes: the precomputed top 3 Medicare codes account for 33.1% of this provider's total Medicare revenue, with the leading individual codes shown as J3111 ($357.8K, 12.2% of Medicare revenue), J2323 ($319.2K, 10.9%), and J3380 ($290.7K, 9.9%). This concentration indicates a substantial share of revenue comes from a narrow set of specialty injectables.

The mix of codes and descriptions indicates an infusion/biologic administration practice: high‑revenue J‑codes include romosozumab (J3111), natalizumab (J2323), vedolizumab (J3380), ocrelizumab (J2350), benralizumab (J0517) and other monoclonal antibodies, and the provider also bills infusion/administration HCPCS/CPT codes such as 96365 and 96413. Together these suggest office‑based delivery of specialty injectable and intravenous therapies for conditions like osteoporosis, multiple sclerosis, inflammatory bowel disease, severe asthma, and immunologic indications.

Competitive standing is mixed across specific products: the provider posts above‑typical national volumes for several biologics (for example J3111 ranks #84 of 970 providers at the 91th percentile and J3380 ranks #107 of 620 at the 83th percentile), but shows modest or below‑typical standing on other agents (J2323 at the 38th percentile and J2350 at the 12th percentile). In aggregate this looks like a focused, regionally meaningful operator for a subset of specialty drugs rather than a dominant national center across all biologics.

There are distinct statistical outliers in utilization patterns that merit attention: 96372 (therapeutic/prophylactic/subcutaneous or intramuscular injection) is labeled an "extreme outlier, far above typical national volume" (773 claims, $7 avg paid/claim, $7K revenue, 99th percentile), while 96365 (initial IV infusion) is also high at the 94th percentile (406 claims, $38 avg paid/claim, $15.4K revenue) and J0897 (denosumab) appears at the 92th percentile (12.2K claims, $219.2K). These high relative volumes in general injection/infusion activity may reflect operational focus on frequent in‑office injections even where dollar impact varies by code.

Clinical/operational capability inference: presence of IV infusion and chemotherapy administration CPTs (96365, 96413, 96366, 96415) alongside many high‑volume J‑codes indicates the practice can perform both subcutaneous/intramuscular injections and multi‑hour IV infusions, though chemotherapy/infusion codes contribute only a small share of total Medicare dollars. This profile supports a service line centered on specialty infusions and injectable biologics rather than primary care office visits.

Tenure and continuity: the NPI was enumerated on 2014-07-11 (~12 years ago), indicating about a decade of Medicare enrollment and an established billing history; that tenure supports longitudinal analysis of utilization or contract performance over multiple policy cycles.

From a payer contracting and utilization‑management perspective, the combination of no Medicaid activity and a concentrated Medicare revenue base (top 3 codes = 33.1%) suggests financial exposure is sensitive to changes in Medicare coverage, formulary positioning, or prior‑authorization practices for those specific biologics. Payors evaluating this provider should prioritize review of utilization trends for the top J‑codes and the unusually high volume of 96372 administration events.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3111	Injection, romosozumab-aqqg, 1 mg	44,730	$10	$357.8K
J2323	Injection, natalizumab, 1 mg	16,800	$20	$319.2K
J3380	Injection, vedolizumab, intravenous, 1 mg	17,100	$20	$290.7K
J2350	Injection, ocrelizumab, 1 mg	7,200	$40	$288K
J0517	Injection, benralizumab, 1 mg	2,070	$130	$273.2K
J2182	Injection, mepolizumab, 1 mg	11,300	$20	$259.9K
J2357	Injection, omalizumab, 5 mg	8,430	$30	$252.9K
J0897	Injection, denosumab, 1 mg	12,180	$20	$219.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,890	$40	$176K
J3245	Injection, tildrakizumab, 1 mg	1,500	$110	$165K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Rosalee Unwin — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	9	10	10,800	$40	$546.8K
J3245	9	20	3,800	$110	$435.3K
J3380	4	20	11,400	$20	$231K
J2323	2	10	8,700	$20	$211.9K
J2357	4	30	4,360	$30	$183.8K
J0517	1	20	1,100	$130	$180.6K
J1569	10	20	3,860	$40	$161.4K
J2182	4	10	5,050	$20	$146.9K
J3111	3	40	12,390	$10	$129.4K
J2356	6	10	7,140	$10	$109.9K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rosalee Unwin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
University Medical Associates Of The Medical University Of South Carol	SC	Family Medicine Physician	$0	$56.6M
Musc Community Physicians	SC	Internal Medicine Physician	$0	$16.7M
University Medical Associates	SC	Pediatrics Physician	$0	$9.2M
Kristi Hunter	GA	General Practice Physician	$6.4M	$0
University Medical Associates Of The Medical University Of South Carol	SC	Obstetrics & Gynecology Physician	$0	$6.1M
Rachel Tedesco	NC	Nurse Practitioner	$5.7M	$0
Musc Community Physicians	SC	Family Medicine Physician	$0	$5.6M
University Medical Associates Of The Medical University Of South Carol	SC	Diagnostic Radiology Physician	$0	$5.4M
Stephen Parks	SC	Family Medicine Physician	$3.9M	$0

Nearby Providers

Other providers in the same ZIP code as Rosalee Unwin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical University Hospital Authority	SC	General Acute Care Hospital	$0	$241.1M
Medical University Hospital Authority	SC	Psychologist	$0	$32.6M
Musc Affiliate Physicians	SC	Family Medicine Physician	$0	$14.7M
Medical University Hospital Authority	SC	Pediatrics Physician	$0	$12.4M
University Medical Associates Of The Medical University Of South Carol	SC	Emergency Medicine Physician	$0	$3.6M
University Medical Associates Of The Medical University Of South Carol	SC	Pediatrics Physician	$0	$3.5M
University Medical Associates Of The Medical University Of South Carol	SC	Psychiatry Physician	$0	$3.3M
Jennifer Douglas	SC	Physician Assistant	$2.9M	$0
University Medical Associates Of The Medical University Of South Carol	SC	Multi-Specialty Clinic/Center	$0	$2.8M
Woodrow Coker	SC	Hospitalist Physician	$2.6M	$0

Rosalee Unwin — Billing Profile & Reimbursement Data

Sign up for Rosalee Unwin — Billing Profile & Reimbursement Data policy alerts

Rosalee Unwin — Billing Profile & Reimbursement Data

Sign up for Rosalee Unwin — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References